1. Natalizumab (Tysabri®) BLA 125104 Medical Review, FDA Nov 2004
2. Natalizumab (Tysabri®) WC 500070715 Refusal CHMP Assessment Report, EMEA Nov 2007
3. Natalizumab (Tysabri®) WC 500095872 Assessment Report, EMEA May 2010
4. Natalizumab (Tysabri®) WC500044686 EPAR Product Information Annex I, EMEA Jan 2012
5. Natalizumab (Tysabri®) SBD 093001 Health Canada, Oct 2005